A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease.
Julie ZimmermannSigne Tandrup SchmidtRamona TrebbienRebecca Jane CoxFan ZhouFrank FollmannGabriel Kristian PedersenDennis ChristensenPublished in: International journal of molecular sciences (2022)
The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF ® 09b contains the TLR3 agonist polyinosinic:polycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective.
Keyphrases
- sars cov
- gene expression
- drug delivery
- immune response
- public health
- dendritic cells
- drug release
- early stage
- healthcare
- respiratory syndrome coronavirus
- cell proliferation
- dna methylation
- mental health
- coronavirus disease
- toll like receptor
- type diabetes
- metabolic syndrome
- skeletal muscle
- climate change
- current status
- smoking cessation
- drug induced